Belfast Health and Social Care Trust
caring supporting improving together

**FOI/38454**

**20 October 2026**

# Incidence and Treatment of Breast Cancer Jul-Sep 2026

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

- Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) **0**
- Abemaciclib + Fulvestrant **6**
- Alpelisib + Fulvestrant **0**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only **<5**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel **6**
- Atezolizumab **0**
- Capivasertib **0**
- Capecitabine as a single agent **44**
- Carboplatin + Paclitaxel **0**
- Elacestrant **0**
- Eribulin as a single agent or in combination **10**
- Everolimus + Exemestane **0**
- Fulvestrant as a single agent **27**
- Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) **0**
- Palbociclib + Fulvestrant **5**
- Parp Inhibitors (Olaparib/Talazoparib) **5**
- Pembrolizumab Monotherapy **<5**
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide **<5**
- Carboplatin + Paclitaxel + Pembrolizumab **0**
- Pertuzumab (Perjeta) + Trastuzumab (Herceptin) **0**
- Phesgo (Pertuzumab + Trastuzumab in a single injection) **0**
- Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole**)** **0**
- Ribociclib + Fulvestrant **<5**
- Sacituzumab Govitecan **<5**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent **21**
- Trastuzumab deruxtecan (Enhertu) **17**
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel **30**
- Trastuzumab emtansine (Kadcyla) **9**

Any other active systemic anti-cancer therapy

Abemaciclib SA **64**, Atezolizumab + NabPaclitaxel **<5**, Capivasertib + Fulvestrant **5**, docetaxel+Cyclophosphamide **<5**, D-Phesgo **7**, EC-D+Trast <5, EC-D 22, ECDPhesgo **16**, EC-Pac/Carbo **22**, EPCPPhesgo **10**, FEC WklyP HER **<5**, Goserelin **6**, Neratinib **<5**, Palbociclib SA **39**, Ribociclib **62**, Tucat Cab Tras **6**, Vinorelbine <**5**, Weekly Pac Phesgo 10, Zoledronic Acid **8**

Where numbers are low, we have indicated <5 rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.